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KEY POINTS
 The unique features of the diagnosis, evaluation, classification and staging of mycosis fungoides
and Se´zary syndrome.
 The evaluation, classification and staging of the nonMF/nonSS CTCLs and the most common sub-
types of CBCLs.
 The response criteria for evaluation of therapeutic efficacy for all subtypes of cutaneous lymphoma.INTRODUCTION
Cutaneous lymphomas are an extremely hetero-
geneous group of non-Hodgkin lymphomas
(NHLs) that manifest in the skin.1,2 Although most
patients do not have evidence by traditional
screening methods of extracutaneous disease at
the time of presentation (and, hence, fit the classic
definition of primary cutaneous lymphoma [PCL]),
those with certain clinical or histologic subtypes
commonly have, or will, develop nodal, visceral,
and/or blood involvement. The prognosis and sur-
vival of patients varies not only on the type of cuta-
neous lymphoma but the stage as well; each
lymphoma has its own best treatments to date,
which are primarily stage based. Because there
is no cure for any of these cutaneous lymphomas,
but treatment can be life saving and insure quality
of life, the overall prognosis for any given patient
begins with the correct diagnosis and staging. It
is the purpose of this article to discuss the evalua-
tion, diagnosis, and staging of the 3 main subcat-
egories of cutaneous lymphoma.Potential conflicts of interest: none.
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CUTANEOUS LYMPHOMA
The annual incidence of PCLs is estimated at 10.0
to 10.7 per million person-years,3,4 and they ac-
count for 19%of cases of extranodal lymphomas.4
The World Health Organization–European Organi-
zation for Research and Treatment of Cancer
(WHO-EORTC) have classified the cutaneous lym-
phomas with primary cutaneous manifestations
into cutaneous T-cell lymphomas (CTCLs) and
cutaneous B-cell lymphomas (CBCLs) (Box 1).5,6
The CBCLs are the least common of the PCLs,
estimated at 3.1 per million person-years in an
assessment of the National Cancer Institute’s Sur-
veillance, Epidemiology, and End Results (SEER)
registry for 2001 to 2005 but making up 29% of
all PCLs.4 The annual incidence rate of CBCLs
steadily increased to an annual rate of 3.92 be-
tween 2006 and 2010.7 The age-adjusted inci-
dence of all types of CTCLs, based on 2 different
sets of SEER, ranged from 6.4 to 7.7 million per-
son-years.4,8 What is clear is that the incidenceUniversity Medical Center, Durham, NC 27710, USA
blished by Elsevier Inc. This is an open access article
org/licenses/by-nc-nd/4.0/).
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Box 1
WHO/EORTC classification of cutaneous
lymphomas
CTCLs and cutaneous NK-cell lymphomas
Mycosis fungoides (MF)
MF variants and subtypes
Folliculotropic MF
Pagetoid reticulosis
Granulomatous slack skin
Se´zary syndrome
Adult T-cell leukemia/lymphoma
Primary cutaneous CD301 lymphoproliferative
disorders
Primary cutaneous anaplastic large cell
lymphoma
Lymphomatoid papulosis
Subcutaneous panniculitis-like T-cell
lymphoma
Extranodal NK/T-cell lymphoma, nasal type
Primary cutaneous peripheral T-cell lymphoma,
unspecified
Primary cutaneous aggressive
epidermotropic CD81 T-cell lymphoma
(provisional)
Cutaneous g/d T-cell lymphoma
Primary cutaneous CD41 small/medium-sized
pleomorphic T-cell lymphoproliferative disor-
der (provisional)
Primary cutaneous acral CD81 T cell lym-
phoma (provisional)
CBCLs
Primary cutaneous marginal zone
lymphoma
Primary cutaneous follicle center lymphoma
Primary cutaneous diffuse large B-cell
lymphoma, leg type
Primary cutaneous diffuse large B-cell
lymphoma, other
Intravascular large B-cell lymphoma
EBV1diffuse large B-cell lymphoma of the
elderly (provisional)
Precursor hematologic neoplasm
Blastic plasmacytoid dendritic cell neoplasm
Abbreviations: MF, mycosis fungoides; NK, natural
killer.
Adapted from Willemze R, Jaffe E, Burg G, et al.
WHO-EORTC classification for cutaneous lymphomas.
Blood 2005;105:3769; with permission.
Olsen644of both CBCLs and CTCLs has continued to in-
crease dramatically and consistently over the
past 3 decades,4 CTCL by 2.9 per million per
decade.8 Based on the numbers available, there
are over 3000 new patients with the diagnosis of
PCL each year.
Mycosis fungoides (MF) is the most common
type of CTCL, comprising 53–54%4,9 to 73%8 of
cases of CTCL in various SEER reviews. Se´zary
syndrome (SS) is classified as a separate entity
from MF by the WHO-EORTC10 but shares the
same histologic criteria and staging as MF and
often evolves from MF.1 SS accounted for 2.5%
of the cases of CTCL in the report by Criscione
and Weinstock.8 The prevalence of MF is likely
more than 50,000 based on survival curves, but
this number is unsubstantiated without a formal
registry. The 10-year survival of patients with MF
with tumor or nodal involvement is compromised
(42% and 20% respectively),5 and the 5-year sur-
vival of patients with SS (who have blood and may
also have node involvement) is 24% in one report.5
Although these patients with tumor or node stage
MF or leukemic blood involvement are the minority
of patients with MF, they represent the potential
progression for which treatments used in those
with lesser disease strive to prevent. There is no
current cure for MF or SS; patients living with MF
or SS endure the chronic symptoms and signs of
their disease and the constant time, cost, and po-
tential side effects of treatment to prevent pro-
gression. Although there are general clinical
characteristics, such as skin (T) stage, or histologic
features, such as large cell transformation (LCT),
that are able to identify those with a worse prog-
nosis in certain situations, there is great heteroge-
neity in these subclasses of PCL and no treatment
available that targets the trigger for the final unre-
mitting growth of the lymphoma that occurs in
some patients. In addition, no genetic markers
are currently available that would help identify sub-
sets of patients more likely to respond to certain
treatments.
Short of a long-term national registry of
patients with cutaneous lymphoma and clear
documentation of the effect on overall prognosis
and survival of the various treatments used and
the potential for clinical, histologic, and genetic
factors to influence the outcome or choice of
treatment, physicians are unable to make the
kind of advances necessary to move toward a
curative treatment of MF and SS. The same is-
sues are present in the other types of CTCLs
and CBCLs, none of which currently have cura-
tive treatment and, because of their relative small
numbers, would benefit greatly from a national
registry.
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approach of the International Society for Cuta-
neous Lymphomas (ISCLC), the EORTC Cuta-
neous Lymphoma Taskforce, and the United
States Cutaneous Lymphoma Consortium
(USCLC) on the diagnosis and staging of both
the CTCLs and CBCLs. Given that there are
certain nuances of MF and SS, including type of
skin lesions, node histology, and potential blood
involvement, that separates these cancers from
the other cutaneous lymphomas, a separate and
distinct staging system exists for MF and SS
from that of the non-MF/non-SS CTCLs and the
CBCLs.MYCOSIS FUNGOIDES AND SE´ZARY
SYNDROME
Diagnosis
Classically, the lesions of MF are described as
patches, plaques, or tumors.1 Patches are flat
but may be scaly or have textural change. Plaques
are defined as slightly raised lesions and can be
smooth, scaly, crusted, or ulcerated. A tumor is
defined as a lesion at least 1 cm in diameter that
has vertical growth or depth. Most of these lesion
subtypes are erythematous on presentation but
can be hyperpigmented. When the presentation
involves diffuse scaling or confluence of patch or
plaque lesions and covers 80% or greater body
surface area (BSA), this meets the criteria for the
term erythroderma.1 There are other clinical pre-
sentations of MF including poikiloderma (a rela-
tively specific finding for MF), hypopigmented
macules and patches, follicular plugging, alopecia,
keratoderma, blisters, and redundant skin within
the axillary or inguinal folds.
The diagnosis of MF or SS is one that requires
clinicopathologic correlation but starts with a
representative skin biopsy suggestive of MF.
Because the type of lesion may affect both the he-
matoxylin and eosin (H&E) and immunophenotyp-
ing results and the potential to find a clone of the
T-cell receptor (TCR) gene rearrangement (GR),
the choice of skin lesion for biopsy is critical. The
most indurated lesion should be biopsied and if
various types of lesions are present, a biopsy of
each type of lesion should be taken: this is impor-
tant to help identify clinical and histologic prog-
nostic factors as well as to help differentiate
between the types of CTCL. For example, a biopsy
of a patch of alopecia may indicate that a patient
has a folliculotropic form of MF in which the base
of the abnormal lymphocytic infiltrate is far deeper
than one would expect with a typical patch lesion.
In general, H&E as well as immunophenotyping
with various T-cell surface markers, including ata minimum CD3, CD4, CD8, CD7, and CD30,
and one B-cell marker, such as CD20, are used
to assess the infiltrate. The lymphocytic infiltrate
may be affected by topical steroids or other topical
or systemic immunosuppressive agents, so it is
important for patients to be off of these, if possible,
for at least the 2 weeks before the skin biopsy; this
is especially true for patch stage lesions. The spe-
cifics of the histologic criteria for the diagnosis of
MF/SS are covered in Dr Kempf’s article in this
issue.
The evaluation for a clonal TCR GR in the skin is
a necessary part of the evaluation as the presence
of a positive clone is supportive evidence of MF:
both gamma and beta testing should be explored
before making a final conclusion as to whether
positive. However, it is important to keep in mind
that a TCR GR clone may be present in benign
skin conditions as well, so the presence of a clone
is not a sine qua non of malignancy. The specifics
of testing for clonality are key, with the BIOMED-2
method currently favored. A biopsy collected on
saline is preferred for clonality testing as the yield
will be increased; but it is clear that, with thick pla-
ques and tumors, this clonality testing can be per-
formed on formalin fixed tissue.
Multiple skin biopsies may be necessary for the
diagnosis in cases of erythroderma where the per-
centage of inflammatory cells is high and the tumor
cells low; in such cases in which the skin biopsy
remains suggestive but not diagnostic of lym-
phoma, a lymph node biopsy or blood studies
indicative of lymphoma may enable a diagnosis
of MF or SS to be made. One must also keep in
mind that a MF-like histology in the skin can be a
manifestation of a drug reaction: most of these
cases typically do not demonstrate clonality of
the TCR GR. When suspected, the potentially of-
fending drug should be discontinued for at least
2 to 3 months before ascribing the condition to
lymphoma.
A useful algorithm focusing on clinicopathologic
correlation was developed by the ISCL in 2005 for
the diagnosis of early MF (Table 1).11 This algo-
rithm is a point scoring system that includes
points for clinical, histologic, molecular, and clon-
ality findings with an overall point score of 4 indi-
cating probable MF. This point scoring was not
meant to be used for the diagnosis of hypopig-
mented MF (although it seems to have validity)
or for SS.Evaluation and Staging
Clinical assessment
A full physical examination is important for evalua-
tion with emphasis on the skin and lymph nodes.
Table 1
Clinicopathologic algorithm for the diagnosis
of early MF
Criteria
Major
(2 Points)
Minor
(1 Point
Each)
Clinical
Persistent and/or
progressive patches/
thin plaques plus
1. Non–sun-exposed
location
2. Size/shape variation
3. Poikiloderma
Any two Any one
Histopathologic
Superficial lymphoid
infiltrate plus
1. Epidermotropism
2. Atypia
Both Either
Molecular/biological
Clonal TCR gene
rearrangement
–– Any
Immunopathologic
1. <50% CD21, 31, 51
T cells
2. <10% CD71 T cells
3. Epidermal/dermal
discordance of CD2,
CD3, CD5 or CD7
–– Any one
Adapted from Pimpinelli N, Olsen EA, Santucci M, et al.
Defining early mycosis fungoides. J Am Acad Dermatol
2005;53:1054.
Olsen646The type of skin lesions and percent BSA covered
by the skin lesions should be noted and will estab-
lish the T stage (Table 2). The T stage has indepen-
dent prognostic significance12,13 as does patch
versus plaque lesions.14 All peripheral or central
lymph node groups should be assessed for any
that are enlarged or abnormal (firm or fixed), and
any lymph node 1.5 cm or greater on examination
should be further assessed by imaging and biopsy.Blood work
The basic blood tests to perform in suspected
MF/SS include a complete blood count (CBC)
with differential, complete metabolic panel and
lactate dehydrogenase (LDH). In addition, there
are several disease-specific tests to help deter-
mine whether there is any significant blood tumor
burden. A Se´zary cell prep includes determining
the percentage of Se´zary cells in the buffy coat
of the CBC. Se´zary cells are lymphocytes with hy-
perconvoluted nuclei that may also be larger than
normal lymphocytes; they are not specific to MF or
SS and can be seen in small numbers in healthy in-
dividuals or patients with inflammatory skindisease.15,16 Although a subjective test, the Se´z-
ary cell prep is, nonetheless, useful as there are
situations where the typical cell surface markers
are lacking on the malignant lymphocytes and
the abnormal cell population would otherwise be
missed on flow cytometry. Flow cytometry offers
an objective test of potential blood involvement
and is particularly useful when focused on
those parameters that have been found to be
associated with blood involvement in MF and SS
(ie, CD4/CD8 ratio, CD41CD26 and CD41CD7
lymphocytes).
The percentage and absolute numbers of both
Se´zary cells and abnormal cells by flow cytometry
are used to determine blood staging, which is
divided into B0, B1, and B2 (Table 2). B0 is essen-
tially normal, and B2 indicates a significant blood
tumor burden that moves a patient to a stage
equal to nodal lymphoma. The absolute number
of abnormal lymphocytes is a mathematical
computation of the absolute number of lympho-
cytes multiplied by either the percent of Se´zary
cells/100 or the percent abnormal cells by flow
cytometry/100.
A blood TCR GR clonality study is important to
perform to help assess B status. B2 blood involve-
ment, according to the ISCL/EORTC consensus
criteria, must also include a clone of the TCR GR
in the blood. Although the guidelines did not
specifically require the clone in the blood to match
that of the skin, this is more or less understood that
it should. Left unsaid is what to do when a patient
has a high Se´zary cell count or abnormal cells on
flow cytometry but a different clone in the blood
than in the skin. There are T-cell clones seen in
the blood that increase with age and would not
be expected to match the malignant clone in the
skin. The author’s personal approach is to note
B0-B2 based on the total abnormal lymphocyte
number and separate notation for clonality for all
B ratings including 1/1 for a positive clone in
the blood that matches the same clone as in
skin, 1/ for a positive clone in the blood but a
different or absent clone in the skin, /1 for no
clone in the blood and a positive clone in the
skin, and / for no clone in either blood or skin.
The same method of testing for clonality in the
blood should be done as that performed in the
skin.
The specific designation of SS, as noted by the
ISCL and USCLC,17 implies that a patient has
erythroderma and B2 blood involvement with a
positive clone.
Radiology
In cases when the skin examination would be
characterized as T1, there are no abnormal
Table 2
ISCL/EORTC/USCLC revisions to the TNMB classification of MF/SS
TNMB
Classification Description of TNMB
Skin
T1 Limited patches, papules, and/or plaques covering <10% of the skin surface; may
further stratify into T1a (patch only) vs T1b (plaque 1/ patch)
T2 Patches, papules, or plaques covering10%of the skin surface; may further stratify into
T2a (patch only) vs T2b (plaque 1/ patch)
T3 One or more tumors (1 cm diameter)
T4 Confluence of erythema covering 80% BSA
Node
N0 No clinically abnormal peripheral or central lymph nodes; biopsy not required
N1 Clinically abnormal peripheral or central lymph nodes; histopathology Dutch grade 1 or
NCI LN0-2
N1a Clone negative
N1b Clone positive
N2 Clinically abnormal peripheral or central lymph nodes; histopathology Dutch grade 2 or
NCI LN3
N2a Clone negative
N2b Clone positive
N3 Clinically abnormal peripheral or central lymph nodes; histopathology Dutch grade 3–4
or NCI LN4
Clone positive or negative
Nx Clinically abnormal peripheral or central lymph nodes, no histologic confirmation
Visceral
M0 No visceral organ involvement
M1 Visceral involvement (must have pathology confirmation, and organ involved should be
specified)
Blood
B0 Absence of significant blood involvement: 5% of peripheral blood lymphocytes are
atypical (Se´zary cells); <15% CD41CD7 or CD41CD26 cells; or <250/ul Se´zary cells,
CD41CD7 or CD41CD26 cells
B0a Clone negative
B0b Clone positive
B1 Low blood tumor burden: >5% of peripheral blood lymphocytes are atypical (Se´zary)
cells greater than B0 criteria but does not meet the criteria of B2
B1a Clone negative
B1b Clone positive
B2 High blood tumor burden: >1000/uL Se´zary cells, CD41CD7 or CD41CD26 cells; or
>40% CD41CD7-cells; or >30% CD41CD26- cells; or CD4/CD8 >10; with positive clone
Adapted fromOlsen EA, Whittaker S, Kim YH, et al. Clinical endpoints and response criteria in mycosis fungoides and Se´z-
ary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas (ISCL), the United States
Cutaneous Lymphoma Consortium (USCLC), and the Cutaneous Lymphoma Task Force of the European Organization
of Research and Treatment of Cancer (EORTC). J Clin Oncol 2011;29:2598–607; and FromOlsen E, Vonderheid E, Pimpinelli
N, et al. Revisions of the staging and classification of mycosis fungoides and Se´zary syndrome: a proposal of the Interna-
tional Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization
of Research and Treatment of Cancer (EORTC). Blood 2007;110:1715.
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staging is B0, only a chest radiograph is re-
commended to screen for visceral disease. For
all other cases, imaging is recommended to
complete staging. Computed tomography (CT)scans of the chest, abdomen, and pelvis 1/
neck are recommended to assess visceral and
nodal disease: contrast enhances the ability to
size the nodes and is preferred unless there is
renal impairment or contrast allergy. PET scans
Table 4
Modified severity weighted assessment tool
Body Region
(% BSA) Patcha Plaqueb Tumorc
Olsen648are not specifically recommended in MF/SS,
although some reports suggest they add staging
accuracy.18 MRI may be used instead of CT but
is usually reserved for cases where there is a his-
tory of contrast allergy.Head (7%)
Neck (2%)
Anterior trunk
(13%)
Arms (8%)
Forearms (6%)
Hands (5%)
Posterior trunk
(13%)
Buttocks (5%)
Thighs (19%)
Legs (14%)
Feet (7%)
Groin (1%)
Subtotal of lesion
BSA
Weighting factor 1 2 4
Subtotal lesion
BSA 3 weighting
factor
mSWATscore5 summation of each column line
in final row above
a Patch 5 any size lesion without significant elevation
above the surrounding uninvolved skin or induration;
b plaque 5 any size lesion that is elevated or indurated;
c tumor 5 any solid or nodular lesion 1 cm in diameter
with evidence of deep infiltration in the skin and/or verti-Biopsies
Liver and spleen involvement can usually be desig-
nated as lymphoma by imaging studies alone, but
other solid organs require a biopsy for confirma-
tion. Bone marrow (BM) biopsy in MF is not gener-
ally recommended unless there is an unexplained
hematologic abnormality exclusive of the ab-
normal lymphocytic population; if performed, a
positive BM biopsy would not be considered
visceral involvement if B2 blood involvement
already exists.
Any lymph node that is 1.5 cm or greater in the
short axis would be considered suspicious of lym-
phoma and an excisional biopsy versus a core bi-
opsy or fine-needle aspirate (FNA) recommended.
In contradistinction to the other cutaneous lym-
phomas, there is a gradation of involvement histo-
logically in the lymph node of MF or SS that falls
short of lymphoma (so-called dermatopathic
lymph node, LN1–LN3), which depends on the
architectural features of the lymph node, features
that cannot be discriminated from frank lym-
phoma by core biopsy or FNA. The lymph node
or N staging is detailed in Table 2. The exception
to an excisional biopsy is if the only lymph node
that is enlarged is a central one that would require
significant surgical risk to remove or if there is onlyTable 3
ISCL/EORTC revisions to the staging of MF/SS
Stage T N M B
IA 1 0 0 0, 1
IB 2 0 0 0, 1
IIA 1–2 1, 2 0 0, 1
IIB 3 0–2 0 0, 1
IIIA 4 0–2 0 0
IIIB 4 0–2 0 1
IVA1 1–4 0–2 0 2
IVA2 1–4 3 0 0–2
IVB 1–4 0–3 1 0–2
From Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions
to the staging and classification of mycosis fungoides and
Se´zary syndrome: a proposal of the International Society
for Cutaneous Lymphomas (ISCL) and the Cutaneous
Lymphoma Task Force of the European Organization of
Research and Treatment of Cancer (EORTC). Blood
2007;110:1719.
cal growth.
From Olsen EA, Whittaker S, Kim YH, et al. Clinical end-
points and response criteria in mycosis fungoides and Se´z-
ary syndrome: a consensus statement of the International
Society for Cutaneous Lymphomas (ISCL), the United
States Cutaneous Lymphoma Consortium (USCLC), and
the Cutaneous Lymphoma Task Force of the European Or-
ganization of Research and Treatment of Cancer (EORTC).
J Clin Oncol 2011;29:2598–607.a need to establish a similar process to that in the
skin or blood; in that case, a core biopsy with flow
cytometry and clonal TCR GR studies may suffice.
If any enlarged nodes are not biopsied, the desig-
nation in staging should be Nx.
Staging
Once the individual classification of TNMB has
been determined, then these can be rolled into
the staging system for MF and SS (Table 3). In a
departure from how the term staging is used with
other NHLs, the TNMB characterization of stage
649Evaluation, Staging and Diagnosis of Cutaneous Lymphomain MF/SS can be noted as initial as well as
maximum and current stage. It is not uncommon
for patients with MF to present with T2N0M0B0
(stage IB) disease, progress to T3N0M0B0 (stage
IIB) disease, be treated, and then currently have
T1N0M0B0 (stage IA) disease. Without the commu-
nication of all these TNMB classifications (stages),
especially in consideration of a clinical trial, a given
patient’s risk for progressive disease would not be
fully communicated or information generated to
help determine best treatments.
Response Assessment
It is important to note how the response to a given
treatment is assessed as most papers in this issue
relate to treatment. The methods in clinical trials of
MF/SS since 2001 have used either the Severity
Weighted Assessment Tool (SWAT) or modifiedTable 5
Response in skin in MF and SS
Complete
response
100% clearance of skin lesions. If
there is any question of
postinflammatory changes or
xerotic skin vs residual disease,
confirmation of clearing is also
necessary in a representative
biopsy or biopsies. If a biopsy
of questionable residual
disease is positive (meets the
criteria of early MF9), then the
response should be labeled as
partial response.
Partial
response
50%–99% clearance of skin
disease from baseline without
new tumors (T3) in patients
with T1, T2 or T4 only skin
disease.
Stable
disease
<25% increase to <50%
clearance in skin disease from
baseline without new tumors
(T3) in patients with T1, T2 or T4
only skin disease.
Progressive
disease
25% increase in skin disease
from baseline or new tumors
(T3) in patients with T1, T2, or T4
only skin disease.
Relapse Any disease recurrence in those
with complete response
From Olsen EA, Whittaker S, Kim YH, et al. Clinical end-
points and response criteria in mycosis fungoides and Se´z-
ary syndrome: a consensus statement of the International
Society for Cutaneous Lymphomas (ISCL), the United
States Cutaneous Lymphoma Consortium (USCLC), and
the Cutaneous Lymphoma Task Force of the European Or-
ganization of Research and Treatment of Cancer (EORTC).
J Clin Oncol 2011;29:2598–607.SWAT (mSWAT) score, which involves deter-
mining the percentage BSA covered by patch,
plaque, or tumor of MF/SS, then multiplying
each lesion BSA by a factor that gives gradations
of weight to patch versus plaque versus tumor
and summing these scores (Table 4).19,20 The
change in SWAT or mSWAT from the beginning
of treatment can be used to assess overall
response. Complete response (CR) in the skin is
defined as complete clinical clearing, partial
response (PR) as 50% to 99% clearing, and
objective response (OR) as the combination of
CR and PR (Table 5).20 There are scoring systems
to assess local response in the skin to agents
applied to limited BSAs, but agents used in this
manner are not able to prevent new lesions from
occurring outside the treated areas. There is a
global scoring system that addresses the entire
TMNB spectrum (Table 6) which is heavily
weighted to the response in skin20; this has only
recently been developed, and most treatment
studies in the past have only addressed the
response in the skin.Table 6
Global response score for MF and SS
Global Skin Nodes Blood Viscera
CR CR All categories have CR/NI.
PR CR All categories do not have
a CR/NI, and no category
has a PD.
PR PR No category has a PD and if
any category is involved
at baseline, at least one
has a CR or PR.
SD PR No category has a PD and if
any category is involved
at baseline, no CR or PR
in any.
SD SD CR, PR, SD in any category
and no category has a
PD.
PD PD in any category.
Relapse Relapse in any category.
Abbreviations: NI, noninvolved; PD, progressive disease;
SD, stable disease.
From Olsen EA, Whittaker S, Kim YH, et al. Clinical end-
points and response criteria in mycosis fungoides and
Se´zary syndrome: a consensus statement of the Interna-
tional Society for Cutaneous Lymphomas (ISCL), the
United States Cutaneous Lymphoma Consortium (USCLC),
and the Cutaneous Lymphoma Task Force of the Euro-
pean Organization of Research and Treatment of Cancer
(EORTC). J Clin Oncol 2011;29:2598–607.
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SE´ZARY SYNDROME CUTANEOUS T-CELL
LYMPHOMAS
Incidence and Prognosis
The most common types of the non-MF/non-SS
CTCLs are the two CD301 lymphoproliferative dis-
orders (LPDs) (ie, primary cutaneous anaplastic
large cell lymphoma [PCALCL] and lymphomatoid
papulosis [LyP]). These CD301 LPDs represent
the most common differential diagnosis for MF.
The prognosis for PCALCL, which, by its definition,
excludes any extracutaneous disease at diagnosis,
is excellent with treatment but like MF/SS, there is
no cure currently, and continued treatment and vig-
ilancemust be used to prevent internal spread. The
prognosis for LyP is excellent, with the potential
for any internal spread being extremely rare.21
LyP not uncommonly occurs with MF/SS and is
discriminated from MF by its presentation (usually
papules of a self-remitting nature) and biopsy find-
ings consistent with one of 5 subtypes (see the
article by Kempf in this issue).
The other types of non-MF/non-SS CTCLs are
rare and also much more concerning in their prog-
nosis compared with the CD301 LPDs. Many pre-
sent with tumors with the main differential being
other primary CTCLs, primary CBCLs, systemic
T- or B-cell lymphomas with skin metastasis, or
even pseudolymphomas. Histologic methods for
assessing these other subtypes are discussed
further in Dr Kempf’s article in this issue. Readers
are directed to publications on each of these cuta-
neous T-cell tumor subtypes for further specifics
on prognosis and treatment.Diagnosis
Like MF/SS, diagnosis of the CD301 LPDs begins
with a skin biopsy; but even more importantly than
inMF, the clinical history is key to the final diagnosis.
Both PCALCL and LyP are characterized histologi-
cally by CD301 T cells (typically CD41) that have
at least 25% of the lymphocyte population defined
as large cells.21 The latter may also be seen in pa-
tientswithMFwith so-called LCT, usually in patients
with tumor stage disease. In this case, the diagnosis
of MF with LCT versus PCALCL is made by the type
of other lesions present: patients with MF typically
also have patches/plaques that have classic histol-
ogy for MF, which is absent in PCALCL. LyP lesions
are small and self-remitting, whereas MF does not
spontaneously improve; PCALC lesions are gener-
ally larger than Lyp lesions and more persistent.
However, when the percentage of large cells ex-
ceeds 75%, the diagnosis is more likely PCALCL
than MF.21 The histologic findings and clinicalparameters of PCALCL and LyP are discussed
further in articles by Drs Kempf and Hughey in this
issue.
Evaluation
Clinical assessment
Like MF and SS, a full physical examination of
patients with possible non-MF/non-SS CTCL is
important at baseline. Unlike MF/SS, any lymph
node that is 1 cm or greater would be of concern
in these patients. Peripheral or central lymph nodes
can be further evaluated by core biopsy or FNAwith
flow and TCR GR clonality studies, because, in
contradistinction to that in MF and SS, there is no
equivalent to dermatopathic nodes in these other
CTCLs which would require an excisional biopsy
to differentiate from frank lymphoma.
Blood work
The basic blood tests to perform in suspected non-
MF/non-SS CTCL include a CBC with differential,
complete metabolic panel, and LDH. Because
there is no blood tumor burden with these condi-
tions, the only reason to do a Se´zary cell prep or
blood flow cytometry would be to exclude MF/SS
in cases where the diagnosis is hazy. BM biopsy
is not recommended in LyP, and guidelines on its
use in the other CTCLs are not clear.
Radiology
PET/CT is recommended for the assessment of
the non-MF and non-SS CTCLs and all CBCLs.
Biopsies
Any abnormality noted on imaging should be
further assessed, and either a core biopsy or
FNA of lymph nodes or visceral organs suspected
of lymphoma should suffice. If there is any confir-
mation of extracutaneous disease, these CTCLs
would no longer be classified as primary cuta-
neous but rather as a systemic lymphoma. How-
ever, in a confusing area, the literature allows for
patients with PCALCL and a single regional lymph
node to remain characterized as PCALCL.
Staging
The staging of non-MF/non-SS CTCLs is different
than MF and SS and is the same as the primary
CBCLs (Table 7, Fig. 1). The major difference
from MF/SS relates to the characterization of the
skin lesions according to size and location relative
to lymph node drainage regions versus the type of
skin lesions and percentage BSA covered used to
classify MF/SS. The staging of LyP defies capture
by current staging systems as the lesions are in a
constant state of flux and occur diffusely over
the body surface.
Table 7
ISCL/EORTC TNM classification of cutaneous lymphomas other than MF/SS
Classification Description
Skin (T) T1 Solitary skin involvement
T1a Solitary lesion <5 cm diameter
T1b Solitary lesion 5 cm diameter
T2 Regional skin involvement: multiple lesions limited to 1 body region or 2 contiguous
body regions
T2a All disease encompassing a <15 cm diameter circular area
T2b All disease encompassing a 15 to 30 cm diameter circular area
T2c All disease encompassing a 30 cm diameter circular area
T3 Generalized skin involvement
T3a Multiple lesions involving 2 noncontiguous body regions
T3b Multiple lesions involving 3 body regions
Lymph
nodes (N)
N0 No clinical or pathologic lymph node involvement
N1 Involvement of one peripheral or central lymph node region that drains an area
of current or prior skin involvement
N2 Involvement of 2 peripheral or central lymph node regions or involvement of
any lymph node region that does not drain in an area of current or prior skin
involvement
N3 Involvement of central lymph nodes
Viscera (M) M0 No evidence of extracutaneous non–lymph node disease
M1 Extracutaneous non–lymph node disease present
T5 any type of skin lesion.
Adapted from Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas
other than mycosis fungoides and Se´zary syndrome: a proposal of the International Society for Cutaneous Lymphomas
(ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer
(EORTC). Blood 2007;110(2):480.
Fig. 1. Body regions defined in the TNM designation of skin involvement (T designation). These body areas are
based on regional lymph node drainage patterns. (From Kim YH, Willemze R, Pimpinelli N, et al. TNM classifi-
cation system for primary cutaneous lymphomas other than mycosis fungoides and Se´zary syndrome: a proposal
of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the
European Organization of Research and Treatment of Cancer (EORTC). Blood 2007;110(2):479–84.)
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There is no mSWAT equivalent for the non-MF/
non-SS CTCLs, although in many cases, the
mSWAT for skin would suffice. CR, PR, and OR inTable 8
LyP response in skin
CR 100% clearance of skin lesions
PR 50%–99% clearance of skin disea
persistent nodules/tumorsb in t
SD <50% increase to <50% clearance
and persistent nodules/tumors
IDAa >50% increase in skin disease fro
tumorsb
PDc 1. Occurrence of larger and pers
2. Extracutaneous spread
Relapse Any disease recurrence in those w
Persistent lesions are defined as lesions that do not show spon
Abbreviations: IDA, increased disease activity; PD, progressi
a The term increased disease activity indicates an increased
imply impaired prognosis.
b Larger lesions are defined as greater than 2 cm in diamet
c Whichever criterion appears first.
Adapted from KempfW, Pfaltz K, VermeerMH, et al. EORTC,
ment of primary cutaneous CD30-positive lymphoproliferative
anaplastic large-cell lymphoma. Blood 2011;118(15):4024–35.
Table 9
Global disease response score in PCALCL
Global Score Definition
CR Complete disappearance
of all clinical evidence
of disease
PR Partial response of
measurable disease
SD Failure to attain CR, PR, or
PD representative of all
disease
PD Progressive disease
Relapse Recurrence of disease in
prior CR
Abbreviation: NI, noninvolved.
Adapted from KempfW, Pfaltz K, VermeerMH, et al. EORTC,
ment of primary cutaneous CD30-positive lymphoproliferative
anaplastic large-cell lymphoma. Blood 2011;118(15):4024–35.the skin are as defined for MF/SS. A global scoring
system has been published for LyP (Table 8) and
PCALCL (Table 9) with potential for the latter to
be used for other non-MF/non-SS PCLs.se from baseline without new larger and
hose with papular disease only
in skin disease from baseline without new larger
in those with papular disease only
m baseline without larger and persistent nodules/
istent nodules/tumors if not present before
ith CR
taneous regression after 12 weeks.
ve disease; SD, stable disease.
number of papulonodular lesions (<2 cm), which do not
er.
ISCL, and USCLC consensus recommendations for the treat-
disorders: lymphomatoid papulosis and primary cutaneous
Skin Nodes Viscera
CR Both categories have CR or NI.
CR Both categories do not have a CR/NI,
and neither category has a PD.
PR No category has a PD; if either
category is involved at baseline, at
least one has a CR or PR.
PR No category has a PD and if either
involved at baseline, no CR or PR
in either.
SD There is CR/NI, PR, or SD in any
category and neither category has
a PD.
PD in any category
Relapse in any category
ISCL, and USCLC consensus recommendations for the treat-
disorders: lymphomatoid papulosis and primary cutaneous
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Incidence
There are 3 main types of primary CBCL (ie, pri-
mary cutaneous marginal zone lymphoma [MZL],
follicular center cell lymphoma (FCCL), and diffuse
large B-cell lymphoma, leg type). Each usually pre-
sents with infiltrated plaques, nodules, or tumors
but each subtype has its own histology, typical
location, potential for progression, and current
treatment algorithm. This is discussed in greater
detail in the articles by Drs Kempf and Pinter-
Brown elsewhere in this issue.
Diagnosis
Like the CTCLs, the CBCLs can be diagnosed by a
combination of H&E, immunophenotyping, and
B-cell clonality studies (immunoglobulin heavy or
light chain rearrangement) performed on represen-
tative skin lesions. The diagnosis hinges much
more on positive clonality than the T-cell lym-
phomas, and there may be difficulty in distinguish-
ing these from pseudolymphomas, which also
typically present clinically with thick plaques or tu-
mors. The presence of an abnormal lymph node
may lead to a final diagnosis: however if positive
for lymphoma, patients would be viewed as having
a systemic lymphoma with skin manifestations
versus a PCL.Evaluation
Clinical assessment
A full physical examination is necessary with any
lymph node that is 1 cm or greater in diameter
considered abnormal.
Blood work
The basic blood tests to perform in primary CBCL
include a CBC with differential, complete meta-
bolic panel, and LDH. There is no leukemic coun-
terpart to the CBCLs as there is with MF/SS. An
evaluation for paraprotein may be done in PCMZL.
Radiology
PET/CT is recommended for assessment of all
CBCLs.
Biopsies
Any abnormality should be further assessed and
either a core biopsy or FNA for suspected lymph
nodes or visceral involvement would suffice. BM
biopsy is required in diffuse large B-cell lym-
phoma, leg type, should be considered in PCFCCL
and is not required in PCMZL. If there is any confir-
mation of extracutaneous disease, patients would
no longer be classified as having a primary CBCL
but rather as having a systemic B-cell lymphoma.Staging
The staging of CBCLs is as with the non-MF/non-
SS CTCLs (see Table 7) with emphasis on the
characterization of the skin lesions according to
size and location relative to the lymph node
drainage regions.
Response Assessment
CR, PR, and OR in the skin are as previously
noted. A global scoring system has been devised
but not yet published although the one used for
PCALCL could be utilized in the interim.SUMMARY
The cutaneous lymphomas are a heterogeneous
group of NHLs that are concerning for multiple rea-
sons: (1) the incidence is on the rise, (2) there is no
cure with current existing therapies, (3) they often
require life-long treatment with systemic medica-
tions in order to prevent progression and to main-
tain quality of life and (4) some types and some
stages of all types of cutaneous lymphoma have
a very poor prognosis. The prognosis may be
best related to maximum TNM or TNMB classifica-
tion and treatment ideally planned based on both
maximum and current TNM(B) classification; this
is not currently considered in treatment algorithms
and is something a registry will be able to sort out.
The collective efforts of investigators in the clinical
and basic research realm and a national registry of
all patients with cutaneous lymphoma give pa-
tients the best chance of finding a cure for these
rare and uncommon cancers.REFERENCES
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